GQG Partners Global Equity Fund Class R EUR Accumulating/  IE00BH480X12  /

The Fund"s investment objective is to seek long term capital appreciation. The Fund may invest in Equity and ELS of companies with any market capitalisation and in any sector located anywhere in the world including, but not limited to, Emerging Market Countries and the United States. The ELS in which the Fund will invest include depositary receipts, which are certificates typically issued by a bank or trust company that represent ownership interests in securities of non-U.S. companies. The Fund will typically hold between 40 and 60 investments with no single portfolio holding anticipated to exceed 7% of the portfolio value. The Fund will exclude investments in companies that derive more than 25% of their revenue from tobacco. In addition, no investments will be made in companies associated with the production of controversial weapons such as anti-personnel mines, cluster munitions, depleted uranium and biological or chemical weapons (i.e. companies screened out by the MSCI ex-Controversial Weapons Index). The Fund may use the following FDIs for investment purposes: participation notes or participatory notes (which do not embed leverage) and/or LEPOs to gain access to inaccessible securities. Investments may also include securities listed on the Russian market (up to 30% of NAV) and China A Shares purchased using the StockConnect. On an ancillary basis the Fund may invest up to 10% of its NAV in other UCITS and exchange traded funds.

The Fund"s investment objective is to seek long term capital appreciation. The Fund may invest in Equity and ELS of companies with any market capitalisation and in any sector located anywhere in the world including, but not limited to, Emerging Market Countries and the United States. The ELS in which the Fund will invest include depositary receipts, which are certificates typically issued by a bank or trust company that represent ownership interests in securities of non-U.S. companies. The Fund will typically hold between 40 and 60 investments with no single portfolio holding anticipated to exceed 7% of the portfolio value. The Fund will exclude investments in companies that derive more than 25% of their revenue from tobacco. In addition, no investments will be made in companies associated with the production of controversial weapons such as anti-personnel mines, cluster munitions, depleted uranium and biological or chemical weapons (i.e. companies screened out by the MSCI ex-Controversial Weapons Index).